Cancer treatments that target the IL-6/STAT3 pathway contribute a therapeutic benefit for inhibiting tumor cell growth.22 A study by Kaoet al.23 has shown that hepatic function, tumor development, and HCC patient survival were all impacted by IL-6 via the STAT3 signal pathway. This evidence concerns the gene STAT3 and hepatocellular carcinoma.